Skip to main content
TipRanks
Go Ultimate75% OFF

Tactile Systems Technology (3L3) Q3 2026 Earnings Report

0 Followers

DE:3L3 Q3 2026 EPS Results

Actual EPS
EUR 0.28
Consensus EPS
EUR 0.25
Beat/Miss
Beat by +EUR 0.03
One Year Ago EPS
EUR 0.33

DE:3L3 Q3 2026 Revenue Results

Actual Revenue
EUR 83.55M
Expected Revenue
EUR 83.67M
Beat/Miss
Missed by -EUR 121.88K
YoY Revenue Growth
+7.12%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/02/2026
Time
After Close
Conference Call
Monday, November 2, 2026
DE:3L3 Upcoming Earnings

Tactile Systems Technology's next earnings date is estimated for February 23, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:3L3 Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 02, 2026|% Change Since:15.80%|
Earnings Call Sentiment|Positive

The call was predominantly positive, supported by sustained 13% lymphedema growth, broad commercial and Medicare gains, improved gross margin, strong cash generation, maintained revenue guidance and higher adjusted EBITDA guidance. The main challenges were the 25.1% airway-clearance revenue decline, the reduced airway-clearance outlook, lower quarterly operating income and net income, adjusted EBITDA margin compression, and the continued time required to improve referral conversion, payer coverage and new-product commercialization.

Company Guidance

The company is maintaining full year 2026 revenue guidance of $360 million to $366 million, representing growth of approximately 9% to 11% year-over-year, and raising adjusted EBITDA guidance to $50 million to $52 million, representing growth of approximately 12% to 16% compared with $44.8 million in 2025; it expects low double-digit growth in lymphedema, full year airway clearance revenue to decline in the mid- to high single digits, meaningful sequential growth in lymphedema in the fourth quarter with a moderation in year-over-year growth, and sequential improvement in fourth-quarter airway clearance revenue with revenue remaining below the prior year. Full year modeling assumptions are GAAP gross margin of approximately 76.5%, GAAP operating expense growth of 10% to 12%, net interest income of approximately $2.4 million, an effective tax rate of approximately 28% and fully diluted weighted average shares outstanding of approximately 23 million, with adjustments of stock-based compensation expense of approximately $8.6 million, depreciation and amortization expense of approximately $7.3 million, executive transition costs of approximately $1.3 million, acquisition-related and integration costs of approximately $1.3 million and litigation-related costs of approximately $1 million.

  • Total Revenue GrowthThird-quarter total revenue was $91.9 million, up $6.1 million or 7.1% year-over-year, as double-digit lymphedema growth more than offset the expected decline in airway clearance. Year-to-date revenue increased 12% to $252.8 million.
  • Sustained Lymphedema GrowthLymphedema revenue increased 13.1% year-over-year to $81.8 million and grew 11% sequentially, marking the fifth consecutive quarter of above-market double-digit growth. Management said the business remains a durable core growth driver with significant market underpenetration.
  • Broad-Based Payer PerformanceLymphedema growth was broad-based across payer channels: Medicare revenue increased approximately 11% year-over-year, commercial revenue increased approximately 17%, and VA revenue was approximately flat. Medicare returned to growth following stabilization of the prior authorization process.
  • Higher Gross MarginThird-quarter gross margin expanded 90 basis points year-over-year to 76.7%, primarily reflecting lower manufacturing costs and favorable product mix. This represented the 12th consecutive quarter of year-over-year gross margin expansion.
  • Raised Adjusted EBITDA GuidanceThe company raised full-year 2026 adjusted EBITDA guidance to $50 million to $52 million from its previous outlook. The range represents approximately 12% to 16% growth compared with $44.8 million in 2025. Year-to-date adjusted EBITDA increased approximately 35% to $29.5 million.
  • Revenue Guidance MaintainedFull-year 2026 revenue guidance was maintained at $360 million to $366 million, representing approximately 9% to 11% year-over-year growth. The outlook reflects low double-digit lymphedema growth and expected sequential improvement in airway clearance revenue during the fourth quarter.
  • Increased Commercial Activity and ReferralsThird-quarter clinic visits increased 19% year-over-year, while referring clinics grew more than 10% year-to-date. Management attributed the progress to investments in sales representatives, CRM technology and market insights that help prioritize referral opportunities.
  • Clinician Marketing and Education ProgressSelect clinician-focused marketing events generated 20% to 45% order growth from participating accounts in the 90 days following the event compared with the 90 days before it. The medical education team educated more than 13,000 clinicians treating lymphedema patients in 2026, already 25% more than in all of 2025.
  • Strategic Accounts Organization EstablishedThe company established a dedicated strategic accounts team to deepen engagement with larger health systems and integrated delivery networks and expand referral opportunities within existing high-volume regional and national accounts.
  • Order Process Efficiency GainsTechnology-enabled improvements reduced average medical record review time by approximately 50%. The company is also replatforming its end-to-end order process through an AI-enabled order management platform and care navigation work.
  • Operating Model Leadership AdditionSteve Kiewiet joined Tactile Medical as Chief Operating Officer in a newly created role overseeing order operations and patient services. Management said the structure is intended to connect the patient journey from referral through shipment and extend process improvements across the organization.
  • LymphaTech Regulatory ProgressLymphaTech received FDA 510(k) clearance for an expanded indication, allowing the scanner to provide circumference and volume measurements to aid in the assessment of lymphedema. The device is already in use and generating revenue at leading academic medical centers.
  • Progress Toward LymphaTech ReimbursementLymphaTech's application for a Category III CPT code is scheduled for final review at the February 2027 meeting. Management described the code as an important step toward broader reimbursement, while noting that Category III is a tracking code rather than a coverage decision.
  • Early Commercial Payer Progress for Head and Neck LymphedemaFollowing publication of six-month randomized controlled trial results for Flexitouch therapy in head and neck cancer-related lymphedema, a small number of commercial payers began removing restrictive experimental and investigational designations from their policies and moving the therapy into covered status.
  • Flexitouch Pro DevelopmentThe company filed a 510(k) application for Flexitouch Pro in October. The product is designed to provide usability and connectivity enhancements while maintaining the clinical effectiveness of Flexitouch, with a targeted commercial launch in the second half of 2027 subject to completion of the regulatory process.
  • MyoSleeve Introduction PlannedTactile Medical is preparing to introduce MyoSleeve in the United States through its partnership with ElastiMed. A focused VA pilot is expected to begin in late Q4 to evaluate patient experience, clinical fit and the appropriate go-to-market model.
  • Strong Cash Position and Capital AllocationThe company ended the quarter with $75.1 million in cash and no outstanding borrowings, up from $69.9 million at the end of the second quarter. Third-quarter operating cash flow was $12 million and more than funded approximately $6.2 million in share repurchases. Approximately $12.5 million remained available under the $25 million repurchase program.
  • Commitment to Operating LeverageManagement reiterated its commitment to operating leverage and expects operating expenses to grow more slowly than revenue as investments mature and scale. The company expects to continue investing in its transformational order-operations platform into 2028 while pursuing top-line and bottom-line growth.
  • Positive Feedback on Next-Generation AffloVestAmong airway-clearance DME customers without excess inventory, management reported strong clinician and patient feedback on the Gen 6 AffloVest. The product remains the only untethered vest, the lightest vest and a connected vest, according to management.

DE:3L3 Earnings History

DE:3L3 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 23, 20272026 (Q4)0.50-0.42――
Nov 02, 20262026 (Q3)0.250.280.33-13.89% (-0.05)
Aug 10, 20262026 (Q2)0.120.310.13142.86% (+0.18)
May 04, 20262026 (Q1)-0.11-0.07-0.1238.46% (+0.05)
Feb 17, 20262025 (Q4)0.400.420.3615.00% (+0.05)
Nov 03, 20252025 (Q3)0.150.330.1971.43% (+0.14)
Aug 04, 20252025 (Q2)0.100.130.16-22.22% (-0.04)
May 05, 20252025 (Q1)-0.07-0.12-0.05-160.00% (-0.07)
Feb 18, 20252024 (Q4)0.290.360.355.26% (+0.02)
Nov 04, 20242024 (Q3)0.170.190.78-75.38% (-0.58)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed